Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.

T HeM A Lopez-OlivoC HurJagpreet Chhatwal

Published in: Alimentary pharmacology & therapeutics (2017)

HCV treatment with DAAs is highly cost-effective in patients with HCV genotypes 2-5 at a $100 000/QALY threshold. Timely HCV treatment would be an optimal strategy from both a public health and economic perspective.

Keyphrases

systematic review
public health
hepatitis c virus
human immunodeficiency virus
combination therapy
smoking cessation